Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Maveropepimut-S Demonstrates Encouraging Activity in Recurrent Ovarian Cancer

August 10th 2021

The subcutaneously administered peptide cancer vaccine maveropepimut-S was found to produce promising activity in heavily pretreated patients with recurrent ovarian cancer.

Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer

August 9th 2021

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

GEN-1 Plus Neoadjuvant Chemo Appears Active, Safe in Advanced Ovarian Cancer

August 8th 2021

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers

July 29th 2021

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Adavosertib, With or Without Olaparib, Showed Promising Efficacy in PARP-Resistant Ovarian Cancer

July 20th 2021

Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.

Immunotherapy GEN-1 Demonstrates Acceptable Risk/Benefit Profile in Advanced Ovarian Cancer

July 20th 2021

The novel gene-mediated immunotherapy GEN-1 showcased satisfactory safety with an acceptable risk/benefit profile when given over a 6-month period with up to 17 doses in newly diagnosed patients with stage III/IV ovarian cancer.

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off

July 16th 2021

The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.

Ceralasertib/Olaparib Combo Elicits Promising Activity in PARP-Resistant Ovarian Cancer

July 15th 2021

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

Dr. O’Malley on the Promise of Antibody-Drug Conjugates in Ovarian Cancer

July 14th 2021

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Dr. Miller on the Safety, Efficacy of Veliparib Vs Other PARP Inhibitors in Ovarian Cancer

July 14th 2021

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian Cancer

July 14th 2021

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Dr. Pothuri on Treatment Considerations for PARP Inhibitors in Ovarian Cancer

July 12th 2021

Bhavana Pothuri, MD, discusses treatment considerations for PARP inhibitors in patients with ovarian cancer.

Galinpepimut-S Plus Pembrolizumab Shows Early Activity in Advanced Ovarian Cancer

July 9th 2021

The combination of galinpepimut-S and pembrolizumab has demonstrated promising clinical immunobiological activity in patients with Wilms Tumor 1–positive, relapsed or refractory, platinum-resistant advanced metastatic ovarian cancer, according to results from an ad-hoc analysis of a phase 1/2 trial.

Dr. O’Malley on the Efficacy of Pembrolizumab in Advanced Ovarian Cancer

July 8th 2021

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers

July 5th 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Dr. Monk on the Mechanism of Action of VB-111 in Ovarian Cancer

June 18th 2021

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of action of VB-111 in patients with ovarian cancer.

Dr. Pothuri on the Role of Maintenance Therapy in BRCA+ Ovarian Cancer

June 11th 2021

Bhavana Pothuri, MD, discusses the role of maintenance therapy in BRCA-positive ovarian cancer.

Maintenance Olaparib/Bevacizumab Provides Substantial PFS, PFS2 Benefit in HRD+ Ovarian Cancer, Irrespective of Disease Stage

June 8th 2021

The addition of olaparib to bevacizumab provided a substantial progression-free survival (PFS) and second PFS benefit over bevacizumab alone in the maintenance treatment of patients with homologous recombination deficiency–positive, newly diagnosed advanced ovarian cancer, regardless of International Federation of Gynecology and Obstetrics disease stage.

Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer

June 7th 2021

Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.